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Abstract
Diabetes is a complex metabolic disorder triggered by the deficient secretion of insulin by the pancreatic β-cell or
the resistance of peripheral tissues to the action of the hormone. Chronic hyperglycemia is the major consequence
of this failure, and also the main cause of diabetic problems. Indeed, several clinical trials have agreed in that tight
glycemic control is the best way to stop progression of the disease. Many anti-diabetic drugs for treatment of type 2
diabetes are commercially available, but no ideal normoglycemic agent has been developed yet. Moreover, weight
gain is the most common side effect of many oral anti-diabetic agents and insulin, and increased weight has been
shown to worsen glycemic control and increase the risk of diabetes progression. In this sense, the inorganic salt
sodium tungstate (NaW) has been studied in different animal models of metabolic syndrome and diabetes, proving
to have a potent effect on normalizing blood glucose levels and reducing body weight, without any hypoglycemic
action. Although the liver has been studied as the main site of NaW action, positive effects have been also
addressed in muscle, pancreas, brain, adipose tissue and intestine, explaining the effective anti-diabetic action of
this salt. Here, we review NaW research to date in these different target organs. We believe that NaW deserves
more attention, since all available anti-diabetic treatments remain suboptimal and new therapeutics are urgently
needed.
Keywords: Diabetes; Metabolic syndrome; Hyperglycemia; Weight
gain; Intestinal glucose absorption; Gluconeogenesis; Glycogen;
Insulin; ERK1/2
Introduction
The control of energy homeostasis and blood glucose
concentrations depends on the exquisite coordination of the function
of several organs and tissues, among them the liver, muscle, fat,
pancreas and the brain. Some of these organs and tissues have major
roles in the use and storage of nutrients in the form of glycogen or
triglycerides and in the release of glucose or free fatty acids into the
blood in periods of metabolic needs, and they all participate in
imbalanced homeostasis during metabolic disorders [1,2]. Diabetes is
a progressive metabolic disease characterized by chronic
hyperglycemia and disturbances of carbohydrate, fat, and protein
metabolism [3]. Diabetes is triggered by the deficient secretion of
insulin by the pancreatic β-cell (T1D) or the resistance of peripheral
tissues to the action of this hormone (T2D). T1D affects 10%, whereas
T2D affects 90% of diabetic patients, and overall they account for 382
million people worldwide [4]. Chronic elevation of blood glucose
levels is the major consequence of insulin deficiency or resistance, and
also the main cause of long-term diabetic problems [5,6]. Tight
glycemic control is widely recognized as the best method to delay
diabetic progression and complications [7-9], but an increased risk of
severe hypoglycemia comes with lower blood glucose levels [10-12].
Furthermore, most T2D patients are overweight, adding another risk
factor for increased morbidity and mortality [12,13].
T1D patients require exogenous insulin administration early in the
development of the disease and a lifelong treatment is required [11].
T2D patients need insulin supplementation in advanced stages of the
disease, when β-cells no longer compensate peripheral insulin
resistance. Despite new formulations have been developed, insulin
injection presents always a higher risk of hypoglycemic events
[11,14,15]. T2D is early treated with one or a combination of the
following drugs: a) Sulfonylureas (SUs) were the first drugs used for
treatment of T2D. SUs lower blood glucose levels by stimulating
insulin secretion from β-cells, but they are associated with a
progressive decline in β-cell function. Hypoglycemia and weight gain
are common effects of SUs therapy [13,16]. b) α-glucosidase inhibitors
are competitive inhibitors of pancreatic α-amylase and intestinal α-
glucosidase in the intestine and delay glucose absorption. Limited
gastrointestinal tolerability has restricted their use [16]. c) Glinides are
insulin releasers that stimulate prandial insulin secretion. They are
associated with weight gain and hypoglycemic events [11,13,16]. d)
Thiazolidinediones are insulin-sensitizers that improve insulin
sensitivity through gene regulation, and weight gain has also been
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associated with their administration [13,16]. e) Biguanides, mainly
represented by metformin, exert their anti-diabetic action through
inhibition of hepatic gluconeogenesis and opposing the action of
glucagon [17], but special considerations must be taken when
administered to patients with renal and/or hepatic impairment [16]. f)
Dipeptidyl peptidase-4 inhibitors (DPP-4) decrease the inactivation of
incretins to stimulate insulin release in a glucose-dependent manner
[18]. Most DPP-4 inhibitors are eliminated through the kidney, so the
same cautions as for metformin must be taken into account [18]. g)
Inhibitors of the main mediator of glucose reabsorption by the kidney,
sodium-glucose cotransporter isoform 2 (SGLT2), have also shown
their great potential [19]. A more complete analysis of the mechanism
of action and side effects of these and other anti-diabetic drugs is out
of the scope of this review. Nevertheless, it is worthy to note that anti-
diabetic drugs receive marketing authorization if they reduce
glycosylated hemoglobin (HbA1c) levels, which are in relation with
blood glucose concentrations [15,20]. However, it has been shown that
anti-diabetic drugs reduce HbA1c without a reduction in clinical
events, and based on trial evidence Boussageon et al. [15] have
proposed that “the clinical efficacy of anti-diabetic drugs is
disappointing and does not support the millions of prescriptions being
written for them”. Hence, given that hypoglycemia and weight gain are
still key limiting steps in maintaining normoglycemia in untreated or
treated diabetic patients, finding and developing new highly effective
anti-diabetic agents is of urgent need for diabetic care.
Efect of Sodium Tungstate (Naw) In Experimental
Animal Models
Tungstate is the oxoanionic form of tungsten, a transition metal
also known as wolfram [21]. Tungstate presents a tetrahedral structure
and it is a phosphate analogue, being widely used as a phosphatase
inhibitor [22-24], although this property is not enough to account for
all the anti-diabetic actions reported to date [25]. Sodium tungstate
(NaW) has shown to be an effective and safety normoglycemic agent
in different T1D and T2D experimental animal models, being
administered orally (ad libitum, in tap water) as a non-invasive easy-
to-use anti-diabetic agent [26,27]. NaW has proven to effectively
normalize blood glucose [26-29] and triglycerides levels [28,30,31], to
restore hepatic glucose metabolism [26,27,29], to stimulate pancreatic
[32-35], cardiac [36] and sexual [37,38] function, to reduce blood
pressure [39-41], to exert anti-obesity [28,30,31,42]; and
immunomodulatory [43] activities. Notably, NaW does not produce
hypoglycemic episodes, and it also stimulates weight loss [31,44]. NaW
concentrations that are active in vitro are similar to the plasma levels
determined in NaW-treated animals [45], and no apparent NaW
toxicity has been reported to date neither in vitro [25] nor in vivo
[26,27,29,36,46]. In fact, NaW has also been proposed as an adjuvant
in the treatment of cancer [47,48], and a protector in liver necrosis and
hepatic failure due to oxidative damage [49,50]. Despite the evidence
described above strongly suggest that NaW exerts beneficial effects at
the physiological level, the mechanism of action of NaW is more
elusive. Most of insulin effects have been mimicked by NaW, but the
molecular events seems to differ. We are going to revise how NaW
affects the activity of tissues involved in energy homeostasis, and how
it improves the metabolic imbalance during insulin resistance and
diabetes.
Liver
Glycogen synthesis and breakdown are among the most important
functions of the liver in order to maintain normal blood glucose levels
during short-term fasting, and induction of hepatic glycogen synthesis
is one of the main anabolic effects of insulin, that is decreased during
diabetes, contributing to abnormal extraction of glucose from the
blood [51]. Oral administration of NaW to streptozotocin (STZ)-
diabetic rats (T1D model) and Zucker diabetic fatty (ZDF) rats (T2D
model) stimulated hepatic glucose metabolism, with a common
increase in glycogen levels [26,27,29,46]. An increase in glycogen
synthase (GS) activity was detected in STZ-diabetic but not in ZDF
rats [26,27,29,46].
Moreover, normalization of fructose 2,6-bisphosphate (F2,6P2)
levels, and restoration of 6-phosphofructo 2-kinase (PFK2); [26,46,52],
liver pyruvate kinase (L-PK) and glycogen phosphorylase (GP)
activities were observed [26,29], whereas glucokinase (GK) activity and
glucose 6-phosphate (G6P) levels were partially recovered [26,29].
Also, mRNA levels of GP, GK and PK [26,27] were enhanced in the
liver after NaW treatment of STZ-diabetic rats. A key discovery in the
insulin-mimetic activity of NaW was that it by-passes the insulin
receptor (IR) to activate GS and to promote glycogen synthesis in
isolated rat hepatocytes [25]. Epidermal growth factor (EGF) and
insulin-like growth factor (IGF) receptors were not activated either
[53]. Notably, NaW had no consistent effect on altered hepatic glucose
metabolism in Insulin receptor substrate (IRS)-2 knockout mice, a
model of T2D [35], which indicates that IRS-2, and maybe the
complete insulin pathway, is required for NaW effects in liver. Like
insulin, NaW induced a rapid and transient phosphorylation, i.e
activation, of extracellular signal-regulated kinase (ERK) 1/2, without
delaying its dephosphorylation [25]. Activation of ERK1/2 was the first
molecular event unequivocally related with NaW signaling, and
stimulation of metabolic but not mitogenic effects of ERK1/2 in the
Chinese hamster ovary (CHO)-R cell line (expressing the wild-type
human insulin receptor) strengthened the different signaling
mechanisms between insulin and NaW [25]. Zafra et al. [53] have
unraveled upstream hepatic NaW signaling involved in ERK1/2
activation in hepatocytes, showing that both Gαi2 and Gβγ subunits of
G-proteins participate in its mechanism of action. NaW induced
activation of the small GTPase Ras, which in turn induced
phoshorylation (activation) of Raf and then mitogen-activated protein
kinase kinase (MEK), the last one being the main kinase activity
involved in ERK1/2 phosphorylation [53] (Figure 1). NaW induced-
ERK1/2 activation triggered phosphorylation of downstream kinases,
including 90 KDa ribosomal S6 kinase (p90rsk) and glycogen synthase
kinase 3β (GSK3β), without activation of protein kinase B (PKB/Akt)
in both isolated hepatocytes [25,27] and rat liver [27]. Remarkably,
PKB/Akt has been recognized as the main contributor to insulin
induced-GSK3β phosphorylation [54]. The normally active
(dephosphorylated) GSK3β is a key player in the insulin pathway, and
its inactivation (phosphorylation) is considered essential for a normal
insulin response [55]. Inhibition of GSK3β by NaW treatment relieved
GS phosphorylation, allowing an increase in glycogen synthetic
activity [53] (Figure 1). Activation of p90rsk has been reported to
inhibit GSK3β and to feedback inhibition of the Ras-ERK pathway
though phosphorylation of the Ras GTP/GDP-exchange factor, Son of
sevenless (SOS) [56]. Besides, it has been shown that NaW exerts an
inhibitory effect over Gcl7p protein phosphatase in yeast, whose
mammalian orthologue is protein phosphatase 1 (PP1), the main
phosphatase acting on GS [57].
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Figure 1: NaW signaling pathway in liver. NaW does not directly
activate IR, or other tyrosine kinase receptors, such as EGF or IGF
receptors in hepatocytes. Rather, it activates Gαi2 and Gβγ subunits
of GPCR, to stimulate the activity of the small GTPase Ras,
initiating the signaling transduction through sequential
phosphorylation of Raf-1, MEK1/2 and ERK1/2, which in turn
phosphorylates GSK3β and p90rsk. Phosphorylated GSK3β is
inactive and alleviates the inhibitory phosphorylation over GS,
favoring activation of glycogen synthesis. Although it has not been
demonstrated for NaW action, p90rsk is known to be involved in
GSK3β inactivation, PP1 activation and negative feedback
upstream in the pathway through inactivation of SOS. PP1 is the
main phosphatase activity participating in GS dephosphorylation
and stimulation of glycogen synthesis, but the actual participation
of NaW in PP1 activation remains to be established. In parallel,
NaW-madiated ERK1/2 activation stimulates c-fos and c-jun, and
inhibits PGC-1 transcriptional expression through yet unknown
mechanisms. Since PGC-1 is a positive modulator, whereas c-fos
and c-jun are negative regulators of the transactivation of
gluconeogenic genes, NaW action finally induces down-regulation
of gluconeogenic enzymes and, hence, the gluconeogenic pathway.
In IRS2 KO mice, NaW was unable to exert consistent effects on
glycogen synthesis and gluconeogenesis, highlighting the
importance of IRS2 in NaW signaling pathway in hepatocytes.
White letter: proteins are modified after NaW treatment. Black
letter: proteins involved in the normal pathway, which are expected
to participate in NaW signaling, although it has not been
determined; Yellow letter: evidence supports these proteins as
potentially involved in NaW signalling; ?: regulatory mechanisms
that have not been confirmed for NaW signalling; P:
phosphorylation.
However, the actual participation of NaW in the in vivo activity of
mammalian PP1 remains to be established.
De novo synthesis of glucose through gluconeogenesis in human
liver is important for maintaining euglycemia in normal conditions
[58], but it is abnormally increased in diabetes, being one of the major
contributors to chronic hyperglycemia [59,60]. Another well-known
metabolic effect of insulin is inhibition of hepatic gluconeogenesis
through down-regulation of the expression of gluconeogenic genes
[59,60].
NaW treatment has shown to normalize mRNA expression of the
three key rate-limiting gluconeogenic enzymes phosphoenolpyruvate
carboxykinase (PEPCK), fructose 1,6-bisphosphatase (FBPase) and
glucose 6-phosphatase (G6Pase) in the liver from STZ-diabetic rats
[26,27], and also PEPCK proteins levels in ZDF [29] and STZ [27]
diabetic rats. A potent inhibitory effect of NaW over G6Pase has also
been reported [61]. Furthermore, it has been shown that diabetes
impairs nuclear translocation of FBPase in rat liver [62-64], which has
been suggested as an insulin-induced sequestration mechanism for
this gluconeogenic enzyme. NaW administration to fasted and fed
STZ-diabetic rats recovered FBPase nuclear accumulation
(unpublished data), in the same way as insulin did [62]. Besides, NaW
normalized expression levels of the transcription factors c-jun and c-
fos, involved in down-regulation of hepatic gluconeogenic genes [65].
Also, despite NaW did not affect expression of the transcription
factors hepatic nuclear factor 4 alpha (HNF4α) and Forkhead box
protein O1 (FOXO1), both important contributors in regulation of
hepatic gluconeogenesis, it did reduce expression of Peroxisome
Proliferator-Activated Receptor (PPAR)-γ coactivator 1 alpha
(PGC1α), a cofactor required for complete induction of PEPCK and
G6Pase expression through HNF4α and FOXO1 transcriptional
activity; [59,60,66]. GSK3β has been shown to act as a key regulator for
the expression of gluconeogenic genes through HNF4α and FOXO1
[55], being a good candidate in mediating NaW effect on hepatic
gluconeogenic activity. Interestingly, the glucocorticoid receptor (GR)
enhances the expression of PGC1, which in turn co-activates both GR
itself and FOXO1 to induce gluconeogenic gene expression [60,67].
NaW has been shown to interact with GR, blocking its activation by
ligand and the consequent ability to bind DNA [68,69]. Moreover,
ERK-mediated phosphorylation of GR has been implicated in cytosolic
retention and inhibition of GR transcriptional activity [70,71], offering
new pathways to explain NaW anti-gluconeogenic actions. Finally and
notably, all these NaW effects in liver metabolism were not observed
in treated non-diabetic rats [26,27,29,46].
Summary: NaW stimulates hepatic glycogen synthesis and inhibits
hepatic endogenous glucose production and release contributing to
normalization of glycemia in diabetes that is dependent on ERK1/2,
but not PKB/Akt activation.
Muscle
Muscle is the major site of insulin-dependent glucose uptake, and
its ability to remove blood glucose is greatly impaired in the diabetic
condition [72]. The main facilitative glucose transporter in muscle is
GLUT4, which is normally located in intracellular compartments and
rapidly translocates to the plasma membrane in response to insulin,
accounting for increased transport activity [73]. GLUT4 expression is
decreased in diabetic rats, but NaW has shown to enhance mRNA and
protein levels, and also translocation of GLUT4 to the plasma
membrane in the diaphragm from NaW-treated STZ-diabetic rats [74]
(Figure 2). In vitro, NaW induced an increase in glucose transport and
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in the amount of GLUT4 mRNA and protein levels in L6 myotubes
[75]. NaW upregulated the transcriptional activity of Glut4 gene
promoter, and this activation depended on the presence of the
myocyte enhancer factor 2 (MEF2) binding site [75] (Figure 2).
Figure 2: NaW signaling pathway in muscle. There is no available
information regarding NaW signaling upstream of ERK1/2 in
muscle, except that again IR is not activated. The same scheme
proposed for liver upstream of ERK1/2 (Scheme 1) was used as a
reference. NaW induced-ERK1/2 activation led to phosphorylation
and inhibition of TSC2, relieving inhibition on MTOR. Activated
MTOR phosphorylates and activates S6K1, which inhibits eIF4E-
BP1, alleviating eIF4E inhibition, and promoting protein
translation. Moreover, ERK1/2 phosphorylates FOXO3 and Mef2
transcription factors. Phosphorylated FOXO3 is inactive and
cannot translocate into the nucleus to transactivate MurF1 and
ATROGIN1 genes, down-regulating the expression of these
important ubiquitin ligases, and reducing the activity of the
ubiquitin-proteasome pathway of protein degradation. Besides,
NaW induces a decline in auto-phagosome formation through the
down-regulation of Bnip3. On the other hand, phosphorylated
Mef2 is active and can enter the nucleus to promote Glut4 gene
expression, which together with above-mentioned eIF4E
stimulation led to enhanced protein synthesis of GLUT4
transporter. Finally, NaW-induced ERK1/2 activation stimulates
fusion of GLUT4-containing vesicles with the plasma membrane,
maybe through direct activation of PLD, enhancing GLUT4 activity
and glucose uptake. White letter: proteins are modified after NaW
treatment; Black letter: proteins involved in the normal pathway,
which are expected to be involved in NaW signaling, although it
has not been determined; P: phosphorylation.
Specifically, an increase in the nuclear content of the transcription
factors MEF2-A; -B and -D isoforms, together with an enhanced
interaction with the promoter binding site, was stimulated by NaW
treatment [75]. Moreover, in contrast to insulin, NaW stimulated
membrane translocation of GLUT4 independently of IR,
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) or PKB/Akt
activation. Also, a lack in 5'AMP-activated protein kinase (AMPK)
activation was observed in response to NaW or insulin [75].
NaW-induced Glut4 gene expression and increased glucose uptake
in L6 myotubes was dependent on ERK1/2 activation, positioning this
kinase as a key mediator in the insulin-mimetic effects of NaW in
muscle. Besides, phospholipase D (PLD) was also involved in the
NaW-induced glucose uptake [75].
Deleterious effects of chronic hyperglycemia trigger accelerated loss
of muscle mass [76]. Like insulin, NaW has shown to stimulate protein
synthesis in L6 myotubes, counteracting dexamethasone-induced
protein degradation [77]. As it has been demonstrated for other
cellular effects, NaW action on protein synthesis depends again on
ERK1/2, but not PKB/Akt activation [77]. ERK1/2 is involved in
phosphorylation and inactivation of tuberin (TSC2) [77], a negative
regulator of the mechanistic target of rapamycin (MTOR). NaW also
induced phosphorylation (activation) of MTOR, which in turn
phosphorylated 70 KDa S6 kinase 1 (S6K1), eukaryotic initiation
factor 4E binding protein-1 (eIF4E-BP1) and eIF4E, promoting
protein synthesis [77] (Figure 2). In parallel, NaW stimulated
phosphorylation (inactivation) and cytosolic arrest, and inhibited
dexamethasone-induced transcriptional activity of the Forkhead box
O3 (FOXO3) transcription factor, which participates in ubiquitin-
proteasome and lysosomal (autophagy) pathways of protein
degradation [77]. Indeed, NaW counteracted the dexamethasone-
induced ubiquitin promoter-dependent expression of the main
ubiquitin ligases, Muscle RING-finger protein 1 (MuRF1) and F-Box
Only Protein 3 (ATROGIN1) [77]. Moreover, NaW impaired
dexamethasone-induced cleavage and phosphatylethanolamine
conjugation of microtubule-associated protein 1 light chain 3 (LC3)
and expression of Bcl-2 and nineteen-kDa interacting protein-37
(Bnip3), two key proteins involved in autophagosome formation [77]
(Figure 2).
Hyperglycemia is associated with a higher risk of cardiac
dysfunction, which in turn results in a high percentage of morbidity
and mortality in diabetic patients [78]. Functional abnormalities of
diabetic heart are attributed to different cellular alterations, such as
reduction in the rate of contraction and relaxation, dysregulation of
Ca2+ homeostasis and altered ionic currents, all of them mediated, at
least in part, through enhanced production of reactive oxygen species
(ROS) and oxidative stress [78,79]. NaW has been shown to reduce
blood pressure in animal models of hypertension [40,41] and
metabolic syndrome [39]. Left ventricular pressure development, the
rate of contraction (+dP/dT), and the rate of relaxation (-dP/dT) were
significantly enhanced in NaW-treated STZ-diabetic rats [36]. This
improvement in contractile deficits elicited by NaW has been
attributed to restoration of intracellular levels of free calcium (Ca2+)
ions and altered ionic currents [79]. Indeed, it has been shown that
NaW activates the large-conductance voltage- and Ca2+-dependent K+
(BK) channel [80,81], and stimulates the release of vasodilator
prostanoids from the vascular wall [39], both participating in the
control of arterial tone through induction of vasodilatation.
Hyperglycemia promotes an abnormal increase in ROS generation
through enhanced activity of different enzyme systems, such as the
mitochondrial respiratory chain, NADPH oxidase (NOX) and
xanthine oxidase (XO) [5,6]. ROS can directly damage lipids, proteins
and DNA, and modulate intracellular signaling pathways and redox
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sensitive transcription factors, altering protein expression. In fact,
redox induced-modifications of protein structure and expression have
been linked to altered muscle activity [82,83]. Interestingly, it has been
demonstrated that myocardial injury involves a xanthine oxidase-
dependent mechanism, and that NaW treatment significantly
decreased cardiac damage and normalize blood pressure [40,41,84].
This is in agreement with the fact that NaW is a well-known inhibitor
of molybdo-enzymes, among them xanthine oxidase [85]. Any effect
of NaW on the other enzyme systems involved in exacerbated ROS
production remains to be established.
Summary: NaW enhances glucose uptake and protein synthesis
through activation of ERK1/2, but not PKB/Akt (or PI3K either in the
case of glucose uptake), contributing to blood glucose normalization
and restoration of muscle mass. Besides, NaW reduces blood pressure
through improvement of contractile deficits and decrease of ROS
production.
Pancreas
The β-cell in the Langerhan's islet from the pancreas is the site of
production of the hormone insulin [86]. In order to maintain
normoglycemia, β-cells secrete insulin in response to different stimuli
[87,88]. In T1D, β-cells are selectively eliminated by an autoimmune
mechanism [89], whereas insulin resistance of peripheral tissues
induces early over-stimulation and later progressive loss of
functionality and finally death (mainly through apoptosis) of β-cells in
T2D [90]. STZ-induced diabetes produces β-cell death, offering a good
model of T1D [91]. A morphometric analysis in diabetic rats showed
that NaW treatment one week before STZ induction preserved normal
islets volume density, volume-weighted mean islets volume, and mass
of β-cells, islets, and pancreas [92], suggesting that NaW protected
from STZ-induced damage. Moreover, blood and pancreas antioxidant
power increased, whilst lipid peroxidation decreased in NaW-treated
diabetic rats [93]. NaW treatment after STZ-induced diabetes in rats
or in IRS-2 knockout diabetic mice significantly decreased β-cell
apoptosis, and also increased β-cell replication, explaining total
increase in β-cell mass [32,35]. The IRS-2 knockout mouse is a good
model for the study of islet survival because most animals by the 8th
week of life start losing β-cell mass due to apoptosis [35]. IRS-2
participates in insulin- and other growth factors-mediated cell survival
and proliferation, and NaW treatment has shown to decrease
upregulated expression of several genes involved in the mitochondrial
apoptotic pathway and inflammatory response in islets lacking IRS-2,
indicating that NaW primarily targets β-cell death mechanisms
through activation of endogenous kinases [35]. Interestingly, NaW
alone induced a little increase in proliferation of the INS-1E rat β-cell
line, but when these cells were incubated with serum from NaW-
treated diabetic rats, the rate of proliferation was greatly enhanced,
suggesting that the proliferative effect of NaW on the pancreatic β-cell
is through indirect mechanisms [32]. A transcriptomic analysis of
pancreas from STZ-diabetic rats has revealed that the majority of
genes whose expression is altered during diabetes, are restored to
different degrees by NaW treatment [32]. Among them, Raf kinase
inhibitory protein (Rkip) gene expression was upregulated in the
diabetic pancreas and normalized by NaW treatment [32], according
with an anti-proliferative function of Rkip in β-cells [94]. ERK1/2 has
been shown to participate in NaW-induced proliferation of INS-1E
cells [32]. Since Rkip inhibits Raf-1 kinase, which phosphorylates
MEK, which in turn phosphorylates ERK1/2, NaW-induced
normalization of Rkip expression leads to an increase in the MAPK
pathway activity, favoring proliferation. Moreover, NaW was able to
restore ERK1/2 phosphorylation in islets from diabetic IRS-2
knockout mice [35], suggesting that IRS-2 is not necessary for NaW
signaling through the ERK pathway in the β-cell. Also, NaW-induced
suppression of upregulated proapoptotic and inflammatory genes in
IRS-2 knockout mice was dependent on the activation of the MAPK
pathway [35].
In the perfused rat pancreas, NaW induced a dose-dependent
stimulation of insulin secretion in the presence of normal (5.5mM) or
moderately high (9mM), but not low (3.2mM) glucose concentrations
[34], explaining in part the absent hypoglycemic effect reported for
NaW treatment. In isolated islets from oral NaW-treated neonatally
STZ (nSTZ)-induced diabetic rats, a model of T2D, a partial recovery
of insulin content and pre-proinsulin mRNA levels was detected,
together with the restoration of β-cell response to an increase in
glucose concentration [95]. NaW did not altered glucagon secretion or
arginine-induced insulin secretion, and the insulinotropic effect of
NaW was abolished by diazoxide, somatostatin and amylin, indicating
that its effect was dependent on normal glucose metabolism and
stimulation of insulin exocytosis by the β-cell [34]. In the BRIN BD11
rat β-cell line, 300μM NaW also increased insulin content, basal
insulin release and the responsiveness to glucose and other
secretagogues [96]. In MIN6 mouse β-cell line, 100μM NaW induced
transient activation of p38 and PI3K, and downstream PI3K-
dependent phosphorylation of S6K1 [97]. Moreover, a selective
inhibitor of the prenylation of the Rho-GTPase Rac1/Cdc42, an
upstream activator of p38, completely blocked the NaW-induced
phosphorylation of p38 in MIN6 cells [97]. p38 phosphorylation has
also been observed in isolated islets from NaW-treated diabetic rats
[33]. p38 and PI3K are known to mediate high glucose-induced
phosphorylation, nuclear translocation and activation of the
pancreatic and duodenal homeobox 1 (PDX-1) transcription factor,
which is involved in pancreas development, insulin expression and β-
cell functionality [98]. NaW stimulated PDX-1 phosphorylation in rat
islets both in vitro and in vivo [33], augmenting the number of insulin
and PDX-1 positive cells in pancreas from NaW-treated STZ-diabetic
rats [32,33]. In MIN6 cells, NaW induced a p38- and PI3K-dependent
nuclear translocation and activation of PDX-1 even at low glucose
concentrations, with a final increase in insulin mRNA levels [97].
However, NaW increased basal insulin release, without affecting
glucose-induced insulin secretion, in a partially p38-dependent
manner [97]. These differences may be explained by the differences in
treatment duration, NaW concentrations and cell models used in each
study.
Summary: NaW promotes β-cell survival through induction of
proliferation and inhibition of apoptosis, and also enhances insulin
production, which is attributable to activation of PDX-1. NaW effects
on β-cell were dependent on MAPK (p38 and ERK) and PI3K
activation.
Adipose tissue
Normal fuel homeostasis involves reciprocal regulation of glucose
and lipid catabolism, in a way that glucose availability inhibits fatty
acid oxidation and promotes fatty acid synthesis, mainly commanded
by insulin signaling [99]. During obesity and insulin resistance,
glucose uptake is impaired and enhanced fatty acid oxidation supplies
intracellular energy, whereas release of free fatty acids into the
circulation is increased for direct utilization by other organs [100].
NaW acts on adipocyte metabolism in an IR-independent manner
[101]. NaW induced up-regulation of GLUT4 mRNA expression and
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increased glucose transport and consumption [102]. NaW treatment
did not alter proliferation or viability, but it decreased triglyceride
accumulation, which was attributed to a reduced gene expression of
enzymes involved in fatty acid synthesis and lipogenesis, such as
lipoprotein lipase (LPL), adipocyte protein 2 (aP2), acetyl-CoA
carboxylase (ACC1) and fatty acid synthase (FAS), and also to a shift
in the mRNA expression profile of transcription factors involved in
adipocyte differentiation, with a decreased expression of CCAAT/
enhancer-binding protein (C/EBP)-α and PPARγ2 and increased
expression of C/EBP-β [42]. Moreover, NaW induced an increase in
mRNA levels of both liver-enriched activator protein (LAP) and liver-
enriched inhibitory protein (LIP) isoforms of C/EBP-β, but an overall
increment in the LIP/LAP ratio explained the decreased adipogenesis
[42]. NaW effect on triglyceride accumulation and C/EBP-β
expression was dependent on ERK1/2, but not p38 or PKB/Akt
activation [42], positioning the MAPK pathway again as a key
signaling cascade for NaW actions in adipocytes. Moreover, NaW
stimulated oxygen consumption both through coupled and uncoupled
respiration in cultured adipocytes, but without affecting mRNA
expression of key oxidative genes, such as PPARα, muscle-carnitine
palmitoyltransferase-1 (mCPT-1), medium chain acyl CoA
dehydrogenase (MCAD), cytochrome C oxidase subunit I (CO-I) or
uncoupling protein (UCP)-2 [42]. In vivo, oral administration of NaW
to high-fat diet-induced obese rats significantly decreased body weight
gain and adiposity without modifying caloric intake, intestinal fat
absorption, or growth rate [31]. NaW induced a reduction of white
adipose tissue mass through apoptosis and reduction in the size of
adipocytes [31]. In contrast to cultured adipocytes, NaW upregulated
expression of UCP-1 in brown adipose tissue [30,31,103] and UCP-2
in white adipose tissue [31], favoring thermogenesis as fatty acid
oxidation. This increased expression, at least for UCP-1 in brown
adipose tissue, was attributed to NaW-induced upregulation of PGC1α
[30,103], a transcription co-activator involved in regulation of
thermogenesis. Notably, NaW treatment also upregulated gene
expression of LPL, aP2, and mCPT-1, but did not affect fatty acid
translocase (FAT/CD36) or acyl-CoA oxidase (ACO) in white adipose
tissue, indicating that NaW increases fatty acid oxidation but limits an
excessive production of ROS [31]. At this regard, it has also been
shown that, at the protein level, NaW induced up-regulation of
aldehyde dehydrogenase and down-regulation of aldehyde reductase
in white adipose tissue [104], and also up-regulation of chaperones
(GRP75/hsp70 and CH60), catalase, transketolase and aldehyde
dehydrogenase in brown adipose tissue [103] from obese rats,
suggesting an overall improvement in the generation of ROS in
adipocytes. Indeed, NaW was able to reverse obesity-induced protein
oxidation [103]. Moreover, proteins involved in lipid metabolism
(monolgyceride lipase, fatty acid binding protein, apolipoprotein A4
and A1, and cholesterol esterase) and cellular structure/cytoskeleton
organization (lamin, annexin, vimentin and vinculin) were up-
regulated in white adipose tissue from obese rats, and NaW treatment
was able to normalize the expression (except for vinculin, which was
further enhanced after NaW treatment), explaining restoration of
metabolism, and decreased remodeling/differentiation of adipocytes
[31,104]. Besides, NaW treatment induced up-regulation of proteins
involved in signal transduction, especially Raf-1 kinase, which in turn
activates the ERK pathway [104].
Interestingly, NaW anti-obesity effects were dependent on an intact
leptin signaling pathway since treatment of obese leptin receptor-
deficient (fa/fa) Zucker rats or obese leptin-deficient (ob/ob) mice did
not result in reduced body weight gain and food intake, or increased
energy expenditure [30]. Nevertheless, transplantation of adipose
tissue from lean mice in ob/ob mice, or treatment with recombinant
leptin restored the NaW-induced actions, despite NaW did not
enhance leptin blood levels [30]. Notably, NaW did not alter
expression of UCP-1, PGC1α or CO-I in brown adipose tissue from
ob/ob mice, which is in agreement with the fact that leptin regulates
(at least) UCP-1 expression by acting centrally through the
sympathetic innervation and not directly on brown adipose tissue [30].
These data also explain the absence of effect of NaW on the expression
of key oxidative genes in cultured adipocytes [42].
Summary: NaW is a potent anti-obesity agent, reducing weight gain
and food intake, and increasing oxygen consumption and
thermogenesis in obese animal models in a leptin-dependent fashion.
ERK1/2, but not PKB/Akt activation, is necessary at least to explain
NaW-mediated inhibition of triglyceride accumulation and decreased
adipogenesis.
Brain
The brain energy homeostasis also suffers the consequences of
metabolic imbalances, such as insulin resistance, hyperglycemia, and
obesity, affecting in turn the feeding behavior and energy expenditure
[105]. NaW is able to cross the blood-brain barrier, reaching a
concentration of 1.3mg/L (4μM) in the cerebrospinal fluid 30 min
after intra-peritoneal injection in rats [44]. Normalization of creatine
kinase activity [106], reduction of ROS and oxidized proteins levels,
and enhancement of antioxidant power [107] has been observed in the
brain from NaW-treated STZ-diabetic rats, suggesting a restoration of
brain metabolism. Also, NaW induced GSK3β phosphorylation in
brain from insulin-resistant rats and in the human neuroblastoma SH-
SY5Y cell line [108]. Since GSK3β is recognized as a key factor in the
insulin signaling pathway, it is expected that NaW-induced GSK3β
inactivation alleviates brain insulin resistance. At this regard, insulin
resistance has been associated with neurodegenerative disorders,
including Alzheimer's disease [109]. The microtubule-associated
protein Tau is a well-known substrate of GSK3β in neurons, and
hyperphosphorylation of Tau has been involved in Alzheimer's disease
[110]. NaW-dependent inactivation of GSK3β and subsequent
dephosphorylation of tau protein (through the ERK1/2, but not PI3K
signaling) opens a new possibility for NaW use in the treatment of this
neurological disorder [108,110]. Leptin is another important hormone
involved in energy homeostasis, mainly secreted by the adipose tissue
in correlation with fat content, and defects in the genes encoding
either leptin or its receptor, or resistance to the action of this hormone,
lead to obesity [111]. Leptin binds to its receptors in the arcuate
nucleus of the hypothalamus, inhibiting neurons that express
orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP),
and activating neurons that express anorexigenic
proopiomelanocortin (POMC) and cocaine- and amphetamine-related
transcript (CART) [105]. Notably, in lean, but not in leptin-deficient
ob/ob mice, NaW decreased NPY/AGRP, and increased CART gene
expression, without altering POMC [30]. A decrease in food intake
and body weight gain was observed 24 hs after injection of NaW
directly in the third cerebro-ventricular cavity, the same effect
produced by leptin injection [44]. As leptin, NaW induced
phosphorylation of Janus kinase (JAK)-2 and the consequent
phosphorylation of Signal transducer and activator of transcription
(STAT)-3 on Tyr705, and also phosphorylation of ERK1/2 and,
subsequently of STAT3 on Ser727, both in vivo in rat hypothalamus
and in vitro in the hypothalamic cell line N29/4 [44]. In N29/4 cells,
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NaW increased mRNA levels of c-fos and c-myc (STAT3 targets) as
soon as 30 min after treatment, and decreased mRNA expression of
AgRP but not NPY. Interestingly, JAK2 activation was necessary for
leptin- and NaW-induced phosphorylation of STAT3 on Tyr705, but
not for NaW-induced phosphorylation of STAT3 on Ser727.
Moreover, JAK2 activation was required for leptin- and NaW-induced
up-regulation of c-myc gene expression, but no for NaW-induced up-
regulation of c-fos. Neither AgRP nor NPY expression was affected by
JAK2 inhibition [44]. On the contrary, inhibition of ERK pathway at
the level of MEK, decreased phosphorylation of STAT3 on Ser727, but
had no effect on phosphorylation of STAT3 on Tyr705, despite leptin
or NaW treatment. In addition, up-regulation of c-fos but not c-myc
was inhibited this time, together with impaired down-regulation of
AgRP after either of both treatments [44].
Excessive caloric intake has been proposed as a negative signal for
remodeling of neuronal networks in the adult hypothalamus, while
caloric restriction potentiates remodeling of brain areas, suggesting
that neuronal plasticity is important for a correct energy balance
[112,113]. NaW treatment has shown to alter expression of proteins in
arcuate (ARC), lateral (LHA) and paraventricular (PVN) nuclei in the
hypothalamus from both lean and obese mice [28]. Expression of
proteins involved in cytoskeleton structure (alpha-internexin (INA),
neurofilament medium polypeptide (NEFM), glial fibrillary acidic
protein (GFAP), βactin, α and β tubulin) and remodeling (collapsin
response mediator protein (CRMP)-2) was influenced by NaW [28].
Interestingly, neurofilament proteins are regulated through MAPK
and STAT3 [114], and CRMP-2 through PI3K, MAPK and GSK3β
[115], which in turn have been shown to be modulated by NaW
[25,27,28,44,108]. In the ARC nucleus, NaW induced an increase in
the number of c-fos positive cells, which has been previously shown to
be mediated by activation of the MAPK pathway [44], and also in
number and size of GFAP-positive astroglia [28]. A reduction of β
tubulin and syntaxin 1 (HPC-1), and an increase of the neurogenic
differentiation (NeuroD)-1 transcription factor and synaptosomal-
associated protein (SNAP)-25 expression was also detected in the ARC
nucleus from NaW-treated mice [28]. Notably, in vivo magnetic
resonance studies showed that NaW treatment had an impact on PVN,
but not ARC nucleus' microstructure, probably due to a higher degree
of neuronal organization [28].
Summary: NaW can act as a leptin-mimetic compound in vivo,
correcting feeding behavior. Moreover, it induces neuronal plasticity
and remodeling of hypothalamic nuclei, maybe modifying the
communication between them.
Intestine
Chronic hyperglycemia during insulin resistance and diabetes is
due to impaired glucose extraction from the blood, to enhanced
endogenous glucose production and release from gluconeogenic
tissues, and to increased glucose absorption at the intestinal level
[116]. STZ-diabetic rats showed increased activity of intestinal sucrase,
affecting the final amount of glucose available for absorption
[117,118]. Moreover, over-expression at the protein, but not mRNA
level, of Na+/glucose co-transporter (SGLT)-1, the main transporter
involved in glucose uptake by the small intestine, accounted for
enhanced glucose transport [118]. Notably, NaW treatment has shown
to normalize both sucrase activity and SGLT-1 expression and activity
in diabetic but not in control rats, explaining the glucose lowering
effect [118]. Besides, NaW has shown to reduce oxidative stress in the
intestinal mucosa from cirrhotic rats [119]. Given that oxidative stress
is a well-known mediator of hyperglycemia-induced damage, NaW
may be involved in restoration of redox balance in the intestine from
diabetic animals.
Summary: NaW restores sucrase and SGLT1 activity in small
intestine, reducing the amount of glucose absorption in diabetic rats. It
is also involved in anti-oxidant mechanisms of intestinal mucosa.
Reproductive system
It is well-known that diabetes impairs reproductive functions, not
only because chronic hyperglycemia leads to glucotoxicity and micro/
macrovascular diseases, but also because insulin signaling itself is
needed for a proper activity of reproductive organs [120]. On one
hand, ovary function and estrous cycle in females, and on the other
hand, testosterone synthesis and total number of Leydig cells in males
are altered, and therefore fertility declines in diabetic animal models
[121,122]. Diminished serum levels of follicle-stimulating (FSH) and
luteinizing (LH) hormones, and consequently, impaired ovarian
production of estrogen and progesterone, and testicular production of
testosterone, are also detected [37,38]. NaW-treated male and female
STZ-diabetic rats showed a recovery of FSH and LH blood levels,
together with an increase in libido and fertility [37,38]. In males, NaW
recovered the number of Leydig cells and serum testosterone levels,
both indirectly by normalizing glucose, insulin and FSH/LH levels,
and directly by increasing IR expression and activating MAPK
pathway and inactivating GSK3β [37]. In females, protein levels of
estrogen (ER) and progesterone (PR) receptors were increased in
ovary, and decreased in uterus from diabetic rats, and NaW treatment
completely restored ER but partially restored PR expression only in
ovary. Contrary to ER, NaW did have a negative effect on PR
expression in the non-diabetic ovary [38]. Moreover, decreased mRNA
expression of FSH and LH receptors was detected in both ovary and
uterus from diabetic rats, but NaW treatment only normalized FSH
receptor expression. Ovaries and uterus from diabetic rats expressed
higher levels of GLUT3, and NaW was able to normalize them [38],
suggesting that normalization of glucose uptake was one mechanism
involved in NaW positive effects. Nevertheless, insulin is as a key
factor in female reproductive function, and NaW has been shown not
to activate the complete insulin signaling pathway in other tissues
[25,27,75]. Moreover, NaW was unable to restore depressed serum
levels of progesterone in diabetic rats, explaining the incomplete effect
of NaW in restoration of reproductive function.
Summary: NaW restores FSH and LH serum levels in both male
and female diabetic rats, contributing to restoration of estrogen (but
not progesterone) and testosterone production, and partial
normalization of reproductive function.
Kidney
The kidney does not only filter the blood and functions as an
excretory organ, but it also participates in endogenous glucose
production [123]. During diabetes, chronic renal reabsorption of
increased amounts of glucose contributes to hyperglycemia [123]. The
kidney is an insulin-sensitive organ, and insulin signaling has been
reported to be impaired in the diabetic kidney [124]. Despite the
kidney is a key organ in the progression of diabetes, little is known
about the effects of NaW on its function. One characteristic
histopathological feature of the diabetic kidney, the so-called
Armanni-Ebstein lesion, is an extensive glycogen deposition in the
tubular cells [125]. This hydropic lesion was detected in STZ-diabetic
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rats, and long-term treatment with NaW was able to completely revert
it [46]. The triggering factors of the pathological accumulation of
glycogen in the diabetic kidney are not known [126], but it is
reasonable to propose that NaW-induced normalization of glycemia is
one important mechanism, although a direct effect on renal
metabolism cannot be ruled out.
Summary: NaW totally reverses the main histopathological lesion of
diabetic kidney, i.e. glycogen accumulation in tubules.
Tungsten vs Vanadium Compounds as Anti-Diabetic
Agents. Clinical Trials in Human Patients
It has been shown that vanadium compounds act as insulin-
mimetics in liver, skeletal muscle and adipose tissue [127]. However,
inorganic vanadium salts have also been associated with undesired
side-effects such as gastrointestinal discomfort, severe decrease in
body weight gain [128], and liver and kidney toxicity in experimental
animal models, independent of the form of vanadium used [129,130].
Some small-scale and short duration trials have proven the beneficial
effects of inorganic vanadium salts on both T1D and T2D human
patients [131-134]; however, despite much lower doses of vanadium
were used than in experimental animals, gastrointestinal discomfort
was the most common toxic effect detected in human patients
[132,133]. Hence, due to potential toxicity of inorganic vanadium salts
at higher doses and long-term therapy in human patients, new organo-
vanadium compounds with higher potency have been investigated,
showing to be much safer and less toxic, at least regarding
gastrointestinal discomfort, and hepatic or renal toxicity
[128,135,136]. Unfortunately, the only study with such an organo-
vanadium compound (bis (2-ethyl-3-hydroxy-4-pyronato)
oxidovanadium(IV)) which has reached preclinical phase II in human
patients, was terminated after three months because of renal
complications (Akesis Pharmaceuticals, Inc., 2009. http://
www.biospace.com/News/akesispharmaceuticals-discontinues-sole-
clinical/123583). Contrary to NaW [25], inorganic vanadium salts
induce the phosphorylation of the insulin receptor on tyrosine
residues [137]. Also, organo-vanadium compounds synergize with
insulin to induce further phosphorylation of the insulin receptor [138],
which may produce undesired hypoglycemic effects. Moreover,
whereas insulin and NaW action on ERK1/2 is transient, vanadate
stimulation lasts up to 20 min [139]. Furthermore, vanadium
compounds activate PKB/Akt [138,140,141], whereas NaW does not
[25,27,42,75,77]. Hence, vanadium salts, either organic or inorganic,
are related with a more potent and complete activation of the insulin
signaling pathway which may have undesired effects, with special
considerations regarding hypoglycemic events due to prolonged
activation.
Several patents have applied for the use of NaW in the treatment of
different human diseases: non-diabetic obesity (patents
WO2002098435 A1; EP1400246 A1), neurodegenerative disorders,
particularly Alzheimer's disease and schizophrenia (patents
WO2007014970 A1; CN101237875 B), diabetes mellitus (EP0755681
A1), and its use as an anti-platelet agent (WO2014096498 A1). These
patents have been published many years ago, some of them have been
withdrawn, others lapsed, but only one of them has reached the
clinical trial phase. A prospective, randomized, placebo-controlled,
double-blind, proof-of-concept trial to address the previously
described anti-obesity activity of NaW was carried out in obese
patients (http://clinicaltrials.gov, identifier NCT00555074). Thirty
moderately obese non-diabetic, mostly normolipidaemic and
normotensive patients received 100 mg NaW or placebo twice a day
during 6 weeks [142]. Data demonstrated that neither weight/percent
of body fat mass, nor energy expenditure/caloric consumption were
significant changed by NaW treatment [142]. Differences in
biochemical parameters, such as fasting plasma glucose and insulin,
lipid profile, leptin and thyroid hormones were not statistically
significant between treated and untreated patients either [142].
Besides, no abnormalities in safety parameters (enzymes reflecting
liver, muscle and kidney function, and other blood proteins) were
detected between the two groups, confirming a low toxicity profile of
NaW [143]. The reasons for the differences in the anti-obesity effect of
NaW between rodents [28,30,31,42] and humans [142] are not known
yet, but they may be attributed to short duration of treatment, to a low
dose of NaW, or both. Since NaW acts without any adverse effects
such as gastrointestinal discomfort, and given the fact that it was
always less toxic than sodium vanadate [143], it is reasonable to
propose that organo-tungsten compounds may offer a better and safer
way to administer this trace element for use in diabetes therapy. No
research has been orientated on this direction so far.
Summary
• Restoration of normoglycemia and normotrygliceridemia,
hallmarks of NaW effects in animal models of metabolic syndrome
and diabetes, are mainly achieved by: diminished intestinal glucose
absorption; increased glycogenesis and decreased gluconeogenesis
in the liver; enhanced glucose uptake by the muscle and adipose
tissue; increased number and improved function of β-cells; and
decreased lipogenesis and adipogenesis in adipose tissue.
• Anti-obesity effects of NaW are dependent on an intact leptin
system.
• All the above-mentioned effects are dependent on ERK1/2
activation by NaW.
• Absent hypoglycemic events of NaW action might be attributed, at
least in part, to partial induction of the insulin signaling pathway,
and stimulation of β-cell insulin secretion by normal or high, but
not low glucose concentrations.
Conclusion
Nowadays, insulin and different oral hypoglycemic drugs are
commercially available; however diabetes mellitus still remains a major
health concern for humans. On the basis of all the research articles
used for this review, it is reasonable to propose that NaW may offer a
potent and complete oral therapy for treatment of T2D patients, and
also for those patients who have higher risk of developing diabetes due
to overweight, hyperglycemia, and hypertension. Although there is no
study addressing co-treatment of NaW with other agents, the use of
NaW as a complement for other anti-diabetic drugs may offer new
possibilities. Furthermore, NaW may serve as a complement in the
treatment of T1D patients with insulin. Its low toxicity profile,
together with the great benefits reported in experimental animal
models, strongly suggest that NaW deserve more attention to reach a
better understanding of the molecular mechanisms involved. Despite
all the overwhelming evidence, only one human trial has been
performed to date, with neither negative nor positive results. The
differences in the effect of NaW between humans and rodents are
unknown, and should be further investigated in order to reproduce the
anti-diabetic and anti-obesity effects in human patients.
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